Related Experiment Videos
Receptor tyrosine kinases as targets for anticancer drugs
Esther Zwick1, Johannes Bange, Axel Ullrich
1Dept of Molecular Biology, Max-Planck-Institut of Biochemistry, Am Klopferspitz 18a, 82152, Martinsried, Germany.
Abstract:
Receptor tyrosine kinases (RTKs) are the primary mediators of the signaling network that transmit extracellular signals into the cell. Gene amplification and/or overexpression of RTK proteins or functional alterations caused by mutations in the corresponding genes or abnormal autocrine-paracrine growth factor loops contribute to constitutive RTK signaling, ultimately resulting in the manifestation of dysregulated cell growth and cancer. The mechanism of uncontrolled RTK signaling that leads to cancer has provided the rationale for anti-RTK drug development. Strategies towards the prevention and interception of RTK signaling include monoclonal antibodies, small-molecule inhibitors, immunotoxins and antisense oligonucleotides.
Insights
Receptor tyrosine kinases (RTKs) transmit signals into cells. Dysregulated RTK signaling drives cancer, leading to the development of targeted anti-RTK therapies like antibodies and small-molecule inhibitors.
Area of Science:
- Molecular Biology
- Cell Signaling
- Cancer Biology
Background:
- Receptor tyrosine kinases (RTKs) are crucial cell signal transmitters.
- Aberrant RTK activity, due to gene amplification, mutations, or growth factor loops, causes uncontrolled cell growth and cancer.
Purpose of the Study:
- To elucidate the role of RTK signaling in cancer development.
- To review the therapeutic strategies targeting RTK signaling pathways.
Main Methods:
- Review of literature on RTK signaling mechanisms.
- Analysis of gene amplification, mutations, and autocrine/paracrine loops in cancer.
- Categorization of anti-RTK therapeutic approaches.
Main Results:
- Constitutive RTK signaling is a hallmark of many cancers.
- Various genetic and epigenetic alterations lead to aberrant RTK activation.
- Multiple drug classes, including monoclonal antibodies and small-molecule inhibitors, are effective against RTKs.
Conclusions:
- Understanding RTK signaling is key to cancer therapy development.
- Targeting RTKs offers a promising strategy for cancer prevention and treatment.
- Diverse anti-RTK therapies are available for clinical application.